KR890005112A - 아졸리딘디온 유도체 - Google Patents

아졸리딘디온 유도체 Download PDF

Info

Publication number
KR890005112A
KR890005112A KR1019880011369A KR880011369A KR890005112A KR 890005112 A KR890005112 A KR 890005112A KR 1019880011369 A KR1019880011369 A KR 1019880011369A KR 880011369 A KR880011369 A KR 880011369A KR 890005112 A KR890005112 A KR 890005112A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
bromine
chlorine
oxygen
Prior art date
Application number
KR1019880011369A
Other languages
English (en)
Other versions
KR900008841B1 (ko
Inventor
웨인 골드스테인 스티븐
사지스 레인하드
Original Assignee
알렌 제이.스피겔
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렌 제이.스피겔, 화이자 인코포레이티드 filed Critical 알렌 제이.스피겔
Publication of KR890005112A publication Critical patent/KR890005112A/ko
Application granted granted Critical
Publication of KR900008841B1 publication Critical patent/KR900008841B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

아졸리딘디온 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 다음 일반식의 스피로-dk졸론 화합물 및 이의 약물학적으로 허용되는 양이온과의 염기 염.
    상기식에서, X는 수소, 불소, 염소, 브롬, 니트로, 트리 플루오로메틸, C1-C4알킬, C1-C4-알콕시 또는 C1-C4알킬티오 이고, Z는 메틸렌, 산소, 황 또는 이미노 이며, Y는 산소 또는 황이고, R은 수소 또는 C1-C4알킬이며, -A=B-D=E-는 -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH- 또는 -CH=CH-CH=N-, 또는 이의 N-옥사이드 유도체를 나타낸다.
  2. 제1항에 있어서, Z가 이미노이고, Y가 산소이며, -A=B-D=E-가 -N=CH-CH=CH-인 화합물.
  3. 제1항에 있어서, X가 수소, 불소, 염소 또는 브롬이고, Z가 이미노이며, Y가 산소이고, -A=B-D=E-는 -N=CH-CH=CH-1의 N-옥사이드 유도체인 화합물.
  4. 제3항에 있어서, X가 브롬이고 R이 C1-C4알킬인 화합물.
  5. 제2항에 있어서, X가 브롬이고 R이 C1-C4알킬인 화합물.
  6. 제2항에 있어서, X가 염소이고 R이 C1-C4알킬인 화합물.
  7. 제6항에 있어서, X가 분자의 6'- 위치에 존재하는 염소이고, R이 메틸인 화합물.
  8. (±)-시스-6'-클로로-2',3'-디하이드로-2'-메틸-스피로-[이미다졸리딘-4,4'-4'H-피라노[2,3-b]-피리딘]-2,5-디온.
  9. (4'S)(2'R)-6'-클로로-2',3'-디하이드로-2'-메틸-스피로[이미다졸리딘-4,4'-4'H-피라노[2,3-b]-피리딘]-2,5-디온.
  10. 당뇨병과 관련된 만성 합병증의 치료에 효과적인 양의 제1항에 따른 화합물과 약제학적으로 허용되는 담체를 포함하는 경구, 국소 또는 비경구 투여에 적절한 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880011369A 1987-09-04 1988-09-03 아졸리딘디온 유도체 KR900008841B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1987/002196 WO1989001775A1 (en) 1987-09-04 1987-09-04 Azolidinedione derivatives
USPCT/US87/02196 1987-09-04

Publications (2)

Publication Number Publication Date
KR890005112A true KR890005112A (ko) 1989-05-11
KR900008841B1 KR900008841B1 (ko) 1990-11-30

Family

ID=22202540

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880011369A KR900008841B1 (ko) 1987-09-04 1988-09-03 아졸리딘디온 유도체

Country Status (21)

Country Link
EP (1) EP0306251A3 (ko)
JP (1) JPS6471882A (ko)
KR (1) KR900008841B1 (ko)
CN (1) CN1022325C (ko)
AU (1) AU595467B2 (ko)
CS (1) CS273186B2 (ko)
DD (1) DD273381A5 (ko)
DK (1) DK488688A (ko)
EG (1) EG18591A (ko)
FI (1) FI901087A0 (ko)
HU (1) HU204832B (ko)
IL (1) IL87590A (ko)
MX (1) MX12896A (ko)
MY (1) MY103765A (ko)
NO (1) NO901016L (ko)
PH (1) PH24957A (ko)
PL (1) PL156798B1 (ko)
PT (1) PT88407B (ko)
WO (1) WO1989001775A1 (ko)
YU (1) YU46863B (ko)
ZA (1) ZA886507B (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068333A (en) * 1990-03-07 1991-11-26 Pfizer Inc. 6-chloro-3,4-dihydro-pyrano [2,3-b]pyridines having the R configuration
DE10210195B4 (de) 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
KR101308227B1 (ko) * 2005-04-21 2013-09-13 이시하라 산교 가부시끼가이샤 니코틴산 유도체 또는 그의 염의 제조 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1088945A (en) * 1976-10-18 1980-11-04 Pfizer Limited Hydantoin derivatives as therapeutic agents
US4176185A (en) * 1979-01-22 1979-11-27 Pfizer Inc. Spiro-quinolylhydantoins
US4226875A (en) * 1979-04-02 1980-10-07 Pfizer Inc. Novel spiro-oxazolidinediones
FR2455046A1 (fr) * 1979-04-25 1980-11-21 Science Union & Cie Nouvelles hydantoines, leur procede de preparation et leur emploi comme medicament
US4235911A (en) * 1979-06-13 1980-11-25 Pfizer Inc. Hydantoin derivatives
US4248882A (en) * 1980-02-12 1981-02-03 Pfizer Inc. Treating diabetes-associated complications with hydantoin amines
EP0065392B1 (en) * 1981-05-13 1985-02-13 Imperial Chemical Industries Plc Pharmaceutical compositions containing spiro succinimide derivatives

Also Published As

Publication number Publication date
YU167788A (en) 1990-06-30
ZA886507B (en) 1990-04-25
CN1031702A (zh) 1989-03-15
CN1022325C (zh) 1993-10-06
IL87590A (en) 1992-07-15
DK488688D0 (da) 1988-09-02
JPS6471882A (en) 1989-03-16
FI901087A0 (fi) 1990-03-02
NO901016D0 (no) 1990-03-02
HU204832B (en) 1992-02-28
EG18591A (en) 1993-06-30
HUT56106A (en) 1991-07-29
NO901016L (no) 1990-05-02
CS591188A2 (en) 1990-06-13
WO1989001775A1 (en) 1989-03-09
JPH0583554B2 (ko) 1993-11-26
AU595467B2 (en) 1990-03-29
PL274504A1 (en) 1989-05-02
DK488688A (da) 1989-04-07
CS273186B2 (en) 1991-03-12
YU46863B (sh) 1994-06-24
AU2184188A (en) 1989-03-09
PT88407B (pt) 1992-10-30
EP0306251A2 (en) 1989-03-08
KR900008841B1 (ko) 1990-11-30
EP0306251A3 (en) 1990-08-01
PT88407A (pt) 1989-07-31
PL156798B1 (pl) 1992-04-30
MX12896A (es) 1993-06-01
IL87590A0 (en) 1989-01-31
PH24957A (en) 1990-12-26
MY103765A (en) 1993-09-30
DD273381A5 (de) 1989-11-15

Similar Documents

Publication Publication Date Title
MXPA05003193A (es) Compuesto de adenina novedoso y uso del mismo.
KR920014816A (ko) 6환 화합물
ES8801651A1 (es) Un procedimiento para preparar fenixialquil(substituido con heterociclo)-isozazoles y furanos
ES482282A1 (es) Un procedimiento para la preparacion de 2,3,4,5-tetrahidro- 1h-3-benzazepinas mercapto-substituidas.
KR880012227A (ko) 도파민 수용체 길항제의 신규사용법
KR890012970A (ko) 테트라히드로 이소퀴놀린 유도체
JPH07504915A (ja) ムスカリン拮抗物質投与による，哺乳動物の眼における眼内圧低下法
KR890014522A (ko) 사이클릭 이미드의 아릴피페라지닐알콕시 유도체, 이의 제조방법 및 약제로서의 이의 용도
KR880009958A (ko) 치환된 3,4-디하이드로-2h-벤조피란, 그의 제조방법 및 용도
KR890005112A (ko) 아졸리딘디온 유도체
FI872807A0 (fi) Menetelmä terapeuttisesti vaikuttavien 3-(N-asyylietyyli-aminoalkyyli)-kromaanien ja -1,4-dioksaanien valmistamiseksi
KR900700098A (ko) 발기부전의 치료겸 진단용 플라복세이트 및 그 유도체
KR920004394A (ko) 티에노디아제핀 이의 제조방법 및 paf-길항 활성을 지닌 약제학적 조성물로서의 이의 용도
KR880007462A (ko) 빈뇨치료용 프로피오페논 유도체
HUT49882A (en) Process for producing new spiro square brackets open chroman-4,4'-imidazolidine square brackets closed derivatives and pharmaceutical compositions comprising these compounds as active ingredient
KR870003098A (ko) 치환된 3-(4-페닐-1-피페라지닐)알킬퀴나졸린-2,4-(1h,3h)디온의 제조방법
KR860004045A (ko) 폴리사이클릭화합물의 제조방법 및 그 약학적 제제
ATE216368T1 (de) Heterocyclische carboxyalkylderivate
KR900001654A (ko) 글리세린 유도체 및 그의 약물학적 용도
KR900701273A (ko) 진토성 에르골린 유도체
KR900701797A (ko) α-아드레날린성 수용체 길항질
KR880009647A (ko) 우울증 치료 활성을 갖는 제제
KR910002855A (ko) 5 6-디하이드로[1H-인돌로[3,2,-c]퀴놀린-6,4-피페리딘] 및 관련화합물, 이의 제조방법 및 약제로서의 용도
IE850161L (en) Penem derivatives and azetidinone intermediates
IL83216A (en) 1((5-(10->9)abeo-6-methylergolin-8beta-yl)methyl)-imidazolidine-(and hexahydropyrimidine)-2,4-dione derivatives,their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19931108

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee